ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Other

November 14, 2018
Thornblade and colleagues endeavored to develop and validate a model that would predict the 2-year risk of recurrence in patients with completely resected node-negative non-small cell lung cancer (NSCLC). Improved recurrence prediction could direct selective use of adjuvant therapy and surveillance imaging in these patients.
September 26, 2018
Using the National Cancer Database, the effect of the timing of computed tomography (CT) surveillance after resection of non-small cell lung cancer on survival was investigated.  Survival was similar for patients undergoing CTs every three months or every six months compared to those undergoing annual surveillance CTs.  More frequent imaging also had
September 25, 2018
A seismic shift occurred today when the NELSON screening trial results were presented at the IASLC 19th World Conference on Lung Cancer (
September 25, 2018
This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.
September 14, 2018
Patient Care and General Interest 3D personalized simulations of patient hearts reportedly allow physicians to better locate and treat arrhythmias.
August 20, 2018
This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.
July 6, 2018
This retrospective study of 328 patients undergoing resection for non-small cell lung cancer demonstrated that sarcopenia determined by psoas muscle mass on computed tomography was associated with increased postoperative complications and was an independent predictor of survival.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival.  Tumor mutational burden was a marker for patient selection for immunotherapy.

Pages